Literature DB >> 33967437

Survival analysis-part 3: intermediate events and the importance of competing risks.

Salil Vasudeo Deo1,2, Vaishali Deo1, Varun Sundaram1.   

Abstract

LEARNING
OBJECTIVES: Understand what events can be labelled as intermediate events in survival analysis.Understand why the Kaplan and Meier method cannot be used in the presence of competing events.Regression analysis in the presence of competing events. © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021.

Entities:  

Keywords:  Bio-statistics; Competing risk models; Fine and Gray model; Hazard rate; Sub-distribution hazard; Survival analysis

Year:  2021        PMID: 33967437      PMCID: PMC8079596          DOI: 10.1007/s12055-021-01151-y

Source DB:  PubMed          Journal:  Indian J Thorac Cardiovasc Surg        ISSN: 0970-9134


  5 in total

1.  The analysis of competing events like cause-specific mortality--beware of the Kaplan-Meier method.

Authors:  Marion Verduijn; Diana C Grootendorst; Friedo W Dekker; Kitty J Jager; Saskia le Cessie
Journal:  Nephrol Dial Transplant       Date:  2010-11-08       Impact factor: 5.992

2.  Adverse events after coronary artery bypass grafting in patients with preoperative metabolic syndrome: A 10-year follow-up of the Veterans Affairs Database.

Authors:  Salil V Deo; Varun Sundaram; Brigid Wilson; Jay Sahadevan; Sri Krishna Madan Mohan; Joseph Rubelowsky; Yakov Elgudin; Brian Cmolik
Journal:  J Thorac Cardiovasc Surg       Date:  2020-08-12       Impact factor: 5.209

3.  Competing risk regression models for epidemiologic data.

Authors:  Bryan Lau; Stephen R Cole; Stephen J Gange
Journal:  Am J Epidemiol       Date:  2009-06-03       Impact factor: 4.897

4.  Introduction to the Analysis of Survival Data in the Presence of Competing Risks.

Authors:  Peter C Austin; Douglas S Lee; Jason P Fine
Journal:  Circulation       Date:  2016-02-09       Impact factor: 29.690

Review 5.  Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement.

Authors:  Peter C Austin; Jason P Fine
Journal:  Stat Med       Date:  2017-01-19       Impact factor: 2.373

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.